Summary:
- Medilink Therapeutics has reported positive Phase III clinical trial results for their antibody-drug conjugate (ADC), Tam-peli (YL202), in Chinese patients with relapsed small-cell lung cancer (SCLC).
- The study demonstrated a statistically significant improvement in overall survival compared to standard chemotherapy, validating the efficacy of targeting the c-Met pathway in this patient demographic.